Mark Schoenberg - 31 Jan 2025 Form 4 Insider Report for UroGen Pharma Ltd. (URGN)

Role
Chief Medical Officer
Signature
/s/ Jason D. Smith, Attorney-in-Fact
Issuer symbol
URGN
Transactions as of
31 Jan 2025
Net transactions value
-$50,698
Form type
4
Filing time
04 Feb 2025, 11:53:22 UTC
Previous filing
12 Sep 2024
Next filing
11 Jun 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction URGN Ordinary Shares Options Exercise +1,334 +0.92% 146,425 31 Jan 2025 Direct F1
transaction URGN Ordinary Shares Sale $8,455 -759 -0.52% $11.14 145,666 31 Jan 2025 Direct F2
transaction URGN Ordinary Shares Options Exercise +3,333 +2.3% 148,999 31 Jan 2025 Direct F1
transaction URGN Ordinary Shares Sale $21,121 -1,896 -1.3% $11.14 147,103 31 Jan 2025 Direct F2
transaction URGN Ordinary Shares Options Exercise +3,333 +2.3% 150,436 31 Jan 2025 Direct F1
transaction URGN Ordinary Shares Sale $21,121 -1,896 -1.3% $11.14 148,540 31 Jan 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction URGN Restricted Stock Units Options Exercise $0 -1,334 -100% $0.000000 0 31 Jan 2025 Ordinary Shares 1,334 Direct F1, F3
transaction URGN Restricted Stock Units Options Exercise $0 -3,333 -50% $0.000000 3,334 31 Jan 2025 Ordinary Shares 3,333 Direct F1, F4
transaction URGN Restricted Stock Units Options Exercise $0 -3,333 -33% $0.000000 6,667 31 Jan 2025 Ordinary Shares 3,333 Direct F1, F5
transaction URGN Restricted Stock Units Award $0 +20,000 $0.000000 20,000 31 Jan 2025 Ordinary Shares 20,000 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.
F2 Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.
F3 The reporting person was granted RSUs on January 31, 2022 representing 4,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2023.
F4 The reporting person was granted RSUs on January 31, 2023 representing 10,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2024.
F5 The reporting person was granted RSUs on January 31, 2024 representing 10,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2025.
F6 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2026, January 31, 2027 and January 31, 2028.